CIDRAP News: DRC Ebola cases hit 3,285 as transmission rate slows
“From Oct. 28 to Nov. 3, only 10 new Ebola cases from five health zones were confirmed in the Democratic Republic of the Congo (DRC), but the World Health Organization (WHO) warns that security issues and poor access continue to hinder the response in rural hot spots. In research findings, a study [Wednesday] highlighted serious long-term symptoms among Ebola survivors…” (Soucheray, 11/6).

Reuters: Johnson & Johnson files for European approval of Ebola vaccine
“Johnson & Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc’s vaccine. J&J said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire strain of the Ebola virus, which most commonly causes outbreaks of the deadly disease…” (Mathias, 11/7).

Additional coverage of how Ebola survivors are assisting in care of patients in DRC is available from Christian Science Monitor.